Sphera Funds Management LTD. Takes Position in Zura Bio Limited (NASDAQ:ZURA)

Sphera Funds Management LTD. bought a new position in shares of Zura Bio Limited (NASDAQ:ZURA) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 738,718 shares of the company’s stock, valued at approximately $2,999,000. Sphera Funds Management LTD. owned approximately 1.10% of Zura Bio as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ZURA. Braidwell LP acquired a new stake in Zura Bio in the 3rd quarter valued at about $10,040,000. Point72 Asset Management L.P. acquired a new stake in Zura Bio in the 2nd quarter valued at about $8,446,000. Great Point Partners LLC increased its position in Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares in the last quarter. Armistice Capital LLC increased its position in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares in the last quarter. Finally, State Street Corp increased its position in Zura Bio by 47.5% in the 3rd quarter. State Street Corp now owns 395,059 shares of the company’s stock valued at $1,604,000 after acquiring an additional 127,300 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ZURA. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research note on Monday, November 18th. Leerink Partners started coverage on shares of Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. Finally, Chardan Capital reduced their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Insider Activity

In other news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.10% of the stock is currently owned by company insiders.

Zura Bio Trading Up 1.5 %

NASDAQ ZURA opened at $2.74 on Thursday. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $6.35. The firm’s 50 day moving average is $3.99 and its 200-day moving average is $3.94.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, research analysts predict that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.